{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T17:10:43Z","timestamp":1794935443392,"version":"4.9.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158775"],"award-info":[{"award-number":["AI158775"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U19AI171110"],"award-info":[{"award-number":["U19AI171110"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158775"],"award-info":[{"award-number":["AI158775"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["U01HL150852"],"award-info":[{"award-number":["U01HL150852"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56902-x","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:44:59Z","timestamp":1739425499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates"],"prefix":"10.1038","volume":"16","author":[{"given":"Prakash","family":"Jadhav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3398-175X","authenticated-orcid":false,"given":"Ahmadullah","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-6962","authenticated-orcid":false,"given":"Bin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhou","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0825-1934","authenticated-orcid":false,"given":"Kan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4853-7931","authenticated-orcid":false,"given":"Xiang","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8531-1243","authenticated-orcid":false,"given":"Alexandra","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0457-0030","authenticated-orcid":false,"given":"Francesc Xavier","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xufang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-4621","authenticated-orcid":false,"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"56902_CR1","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li, G., Hilgenfeld, R., Whitley, R. & De Clercq, E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat. Rev. Drug Discov. 22, 449\u2013475 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"56902_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1126\/science.adk5868","volume":"382","author":"BK Shoichet","year":"2023","unstructured":"Shoichet, B. K. & Craik, C. S. Preparing for the next pandemic. Science 382, 649\u2013650 (2023).","journal-title":"Science"},{"key":"56902_CR3","doi-asserted-by":"publisher","first-page":"eabo7201","DOI":"10.1126\/science.abo7201","volume":"382","author":"ML Boby","year":"2023","unstructured":"Boby, M. L. et al. Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors. Science 382, eabo7201 (2023).","journal-title":"Science"},{"key":"56902_CR4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170236","volume":"133","author":"M Karim","year":"2023","unstructured":"Karim, M., Lo, C. W. & Einav, S. Preparing for the next viral threat with broad-spectrum antivirals. J. Clin. Investig. 133, e170236 (2023).","journal-title":"J. Clin. Investig."},{"key":"56902_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29517-9","volume":"13","author":"SR Radoshitzky","year":"2023","unstructured":"Radoshitzky, S. R. et al. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro. Sci. Rep. 13, 3131 (2023).","journal-title":"Sci. Rep."},{"key":"56902_CR6","doi-asserted-by":"publisher","first-page":"e00162","DOI":"10.1128\/CMR.00162-20","volume":"34","author":"JJ Malin","year":"2020","unstructured":"Malin, J. J., Su\u00e1rez, I., Priesner, V., F\u00e4tkenheuer, G. & Rybniker, J. Remdesivir against COVID-19 and Other Viral Diseases. Clin. Microbiol. Rev. 34, e00162\u201320 (2020).","journal-title":"Clin. Microbiol. Rev."},{"key":"56902_CR7","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","volume":"28","author":"F Kabinger","year":"2021","unstructured":"Kabinger, F. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat. Struct. Mol. Biol. 28, 740\u2013746 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"56902_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1007\/s00044-022-02951-6","volume":"31","author":"RP Joyce","year":"2022","unstructured":"Joyce, R. P., Hu, V. W. & Wang, J. The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations. Med. Chem. Res. 31, 1637\u20131646 (2022).","journal-title":"Med. Chem. Res."},{"key":"56902_CR9","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 374, 1586\u20131593 (2021).","journal-title":"Science"},{"key":"56902_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1021\/acs.accounts.2c00735","volume":"56","author":"B Tan","year":"2023","unstructured":"Tan, B., Joyce, R., Tan, H., Hu, Y. & Wang, J. SARS-CoV-2 main protease drug design, assay development, and drug resistance studies. Acc. Chem. Res. 56, 157\u2013168 (2023).","journal-title":"Acc. Chem. Res."},{"key":"56902_CR11","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","volume":"65","author":"Y Unoh","year":"2022","unstructured":"Unoh, Y. et al. Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19. J. Med. Chem. 65, 6499\u20136512 (2022).","journal-title":"J. Med. Chem."},{"key":"56902_CR12","doi-asserted-by":"publisher","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","volume":"67","author":"CMN Allerton","year":"2024","unstructured":"Allerton, C. M. N. et al. A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19. J. Med. Chem. 67, 13550\u201313571 (2024).","journal-title":"J. Med. Chem."},{"key":"56902_CR13","doi-asserted-by":"publisher","first-page":"3935","DOI":"10.1021\/acs.jmedchem.3c02248","volume":"67","author":"VW Shurtleff","year":"2024","unstructured":"Shurtleff, V. W. et al. Invention of MK-7845, a SARS-CoV-2 3CL protease inhibitor employing a novel difluorinated glutamine mimic. J. Med. Chem. 67, 3935\u20133958 (2024).","journal-title":"J. Med. Chem."},{"key":"56902_CR14","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acscentsci.3c00538","volume":"9","author":"Y Hu","year":"2023","unstructured":"Hu, Y. et al. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. ACS Cent. Sci. 9, 1658\u20131669 (2023).","journal-title":"ACS Cent. Sci."},{"key":"56902_CR15","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41422-022-00640-y","volume":"32","author":"MD Sacco","year":"2022","unstructured":"Sacco, M. D. et al. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res. 32, 498\u2013500 (2022).","journal-title":"Cell Res."},{"key":"56902_CR16","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","volume":"613","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature 613, 558\u2013564 (2022).","journal-title":"Nature"},{"key":"56902_CR17","doi-asserted-by":"publisher","first-page":"eadd7197","DOI":"10.1126\/sciadv.add7197","volume":"8","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system. Sci. Adv. 8, eadd7197 (2022).","journal-title":"Sci. Adv."},{"key":"56902_CR18","doi-asserted-by":"crossref","unstructured":"Jochmans, D. et al. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a protease inhibitor in vitro and confer resistance to Nirmatrelvir. mBio, 14, e0281522 (2023).","DOI":"10.1128\/mbio.02815-22"},{"key":"56902_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39704-x","volume":"14","author":"M Kiso","year":"2023","unstructured":"Kiso, M. et al. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir. Nat. Commun. 14, 3952 (2023).","journal-title":"Nat. Commun."},{"key":"56902_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37773-6","volume":"14","author":"R Abdelnabi","year":"2023","unstructured":"Abdelnabi, R. et al. Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in female Syrian hamsters and retains partial susceptibility to treatment. Nat. Commun. 14, 2124 (2023).","journal-title":"Nat. Commun."},{"key":"56902_CR21","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/cid\/ciad494","volume":"78","author":"NS Zuckerman","year":"2023","unstructured":"Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir resistance - de novo E166V\/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir\/ritonavir monotherapy leading to clinical and virological treatment failure - a case report. Clin. Infect. Dis. 78, 352\u2013355 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"56902_CR22","doi-asserted-by":"publisher","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","volume":"6","author":"W Rut","year":"2020","unstructured":"Rut, W. et al. Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci. Adv. 6, eabd4596 (2020).","journal-title":"Sci. Adv."},{"key":"56902_CR23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","volume":"587","author":"D Shin","year":"2020","unstructured":"Shin, D. et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 587, 657\u2013662 (2020).","journal-title":"Nature"},{"key":"56902_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38031-5","volume":"14","author":"PM Wydorski","year":"2023","unstructured":"Wydorski, P. M. et al. Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin. Nat. Commun. 14, 2366 (2023).","journal-title":"Nat. Commun."},{"key":"56902_CR25","doi-asserted-by":"publisher","first-page":"7561","DOI":"10.1021\/acs.jmedchem.2c00303","volume":"65","author":"H Tan","year":"2022","unstructured":"Tan, H., Hu, Y., Jadhav, P., Tan, B. & Wang, J. Progress and challenges in targeting the SARS-CoV-2 Papain-like protease. J. Med. Chem. 65, 7561\u20137580 (2022).","journal-title":"J. Med. Chem."},{"key":"56902_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37254-w","volume":"14","author":"BC Sanders","year":"2023","unstructured":"Sanders, B. C. et al. Potent and selective covalent inhibition of the papain-like protease from SARS-CoV-2. Nat. Commun. 14, 1733 (2023).","journal-title":"Nat. Commun."},{"key":"56902_CR27","doi-asserted-by":"publisher","first-page":"e202200440","DOI":"10.1002\/cmdc.202200440","volume":"17","author":"AK Ghosh","year":"2022","unstructured":"Ghosh, A. K., Mishevich, J. L., Mesecar, A. & Mitsuya, H. Recent drug development and medicinal chemistry approaches for the treatment of SARS-CoV-2 infection and COVID-19. ChemMedChem 17, e202200440 (2022).","journal-title":"ChemMedChem"},{"key":"56902_CR28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1126\/science.adm9724","volume":"383","author":"B Tan","year":"2024","unstructured":"Tan, B. et al. Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model. Science 383, 1434\u20131440 (2024).","journal-title":"Science"},{"key":"56902_CR29","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/acs.jmedchem.1c01307","volume":"65","author":"Z Shen","year":"2022","unstructured":"Shen, Z. et al. Design of SARS-CoV-2 PLpro inhibitors for COVID-19 antiviral therapy leveraging binding cooperativity. J. Med. Chem. 65, 2940\u20132955 (2022).","journal-title":"J. Med. Chem."},{"key":"56902_CR30","doi-asserted-by":"publisher","first-page":"116011","DOI":"10.1016\/j.ejmech.2023.116011","volume":"264","author":"P Jadhav","year":"2024","unstructured":"Jadhav, P. et al. Structure-based design of SARS-CoV-2 papain-like protease inhibitors. Eur. J. Med. Chem. 264, 116011 (2024).","journal-title":"Eur. J. Med. Chem."},{"key":"56902_CR31","doi-asserted-by":"publisher","first-page":"102323","DOI":"10.1016\/j.xpro.2023.102323","volume":"4","author":"H Tan","year":"2023","unstructured":"Tan, H., Hu, Y. & Wang, J. FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro). STAR Protoc. 4, 102323 (2023).","journal-title":"STAR Protoc."},{"key":"56902_CR32","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1021\/acscentsci.1c00519","volume":"7","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-based reporter assay. ACS Cent. Sci. 7, 1245\u20131260 (2021).","journal-title":"ACS Cent. Sci."},{"key":"56902_CR33","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020106275","volume":"39","author":"T Klemm","year":"2020","unstructured":"Klemm, T. et al. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 39, e106275 (2020).","journal-title":"EMBO J."},{"key":"56902_CR34","doi-asserted-by":"publisher","first-page":"eado4288","DOI":"10.1126\/sciadv.ado4288","volume":"10","author":"MR Garnsey","year":"2024","unstructured":"Garnsey, M. R. et al. Discovery of SARS-CoV-2 papain-like protease (PL(pro)) inhibitors with efficacy in a murine infection model. Sci. Adv. 10, eado4288 (2024).","journal-title":"Sci. Adv."},{"key":"56902_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202317376","volume":"15","author":"L Zhang","year":"2023","unstructured":"Zhang, L. et al. Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infection. EMBO Mol. Med. 15, e17376 (2023).","journal-title":"EMBO Mol. Med."},{"key":"56902_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00922-z","volume":"9","author":"G Wang","year":"2024","unstructured":"Wang, G. et al. Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV. NPJ Vaccines 9, 133 (2024).","journal-title":"NPJ Vaccines"},{"key":"56902_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41590-024-01787-z","volume":"25","author":"V Fumagalli","year":"2024","unstructured":"Fumagalli, V. et al. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat. Immunol. 25, 633\u2013643 (2024).","journal-title":"Nat. Immunol."},{"key":"56902_CR38","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202317580","volume":"15","author":"V Fumagalli","year":"2023","unstructured":"Fumagalli, V. et al. Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune responses. EMBO Mol. Med. 15, e17580 (2023).","journal-title":"EMBO Mol. Med."},{"key":"56902_CR39","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.abb8925","volume":"368","author":"JB Moore","year":"2020","unstructured":"Moore, J. B. & June, C. H. Cytokine release syndrome in severe COVID-19. Science 368, 473\u2013474 (2020).","journal-title":"Science"},{"key":"56902_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/rmv.2141","volume":"30","author":"EA Coomes","year":"2020","unstructured":"Coomes, E. A. & Haghbayan, H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev. Med. Virol. 30, 1\u20139 (2020).","journal-title":"Rev. Med. Virol."},{"key":"56902_CR41","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","volume":"384","author":"AC Gordon","year":"2021","unstructured":"Gordon, A. C. et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N. Engl. J. Med. 384, 1491\u20131502 (2021).","journal-title":"N. Engl. J. Med."},{"key":"56902_CR42","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41577-021-00553-8","volume":"21","author":"SA Jones","year":"2021","unstructured":"Jones, S. A. & Hunter, C. A. Is IL-6 a key cytokine target for therapy in COVID-19? Nat. Rev. Immunol. 21, 337\u2013339 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"56902_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1001\/jama.2021.11330","volume":"326","author":"M Shankar-Hari","year":"2021","unstructured":"Shankar-Hari, M. et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326, 499\u2013518 (2021).","journal-title":"JAMA"},{"key":"56902_CR44","doi-asserted-by":"publisher","first-page":"2003006","DOI":"10.1183\/13993003.03006-2020","volume":"56","author":"LYC Chen","year":"2020","unstructured":"Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. & Sekhon, M. S. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur. Respir. J. 56, 2003006 (2020).","journal-title":"Eur. Respir. J."},{"key":"56902_CR45","doi-asserted-by":"publisher","first-page":"155637","DOI":"10.1016\/j.cyto.2021.155637","volume":"146","author":"N Todorovi\u0107-Rakovi\u0107","year":"2021","unstructured":"Todorovi\u0107-Rakovi\u0107, N. & Whitfield, J. R. Between immunomodulation and immunotolerance: the role of IFN\u03b3 in SARS-CoV-2 disease. Cytokine 146, 155637 (2021).","journal-title":"Cytokine"},{"key":"56902_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki, R. et al. Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184, 149\u2013168.e117 (2021).","journal-title":"Cell"},{"key":"56902_CR47","doi-asserted-by":"publisher","first-page":"eadi9379","DOI":"10.1126\/sciadv.adi9379","volume":"10","author":"BA Krishna","year":"2024","unstructured":"Krishna, B. A. et al. Spontaneous, persistent, T cell-dependent IFN-\u03b3 release in patients who progress to Long Covid. Sci. Adv. 10, eadi9379 (2024).","journal-title":"Sci. Adv."},{"key":"56902_CR48","doi-asserted-by":"publisher","first-page":"eadn0136","DOI":"10.1126\/scitranslmed.adn0136","volume":"16","author":"C Li","year":"2024","unstructured":"Li, C. et al. Comparative single-cell analysis reveals IFN-\u03b3 as a driver of respiratory sequelae after acute COVID-19. Sci. Transl. Med. 16, eadn0136 (2024).","journal-title":"Sci. Transl. Med."},{"key":"56902_CR49","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.virusres.2014.01.025","volume":"194","author":"AM Mielech","year":"2014","unstructured":"Mielech, A. M., Chen, Y., Mesecar, A. D. & Baker, S. C. Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities. Virus Res. 194, 184\u2013190 (2014).","journal-title":"Virus Res."},{"key":"56902_CR50","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"YM B\u00e1ez-Santos","year":"2015","unstructured":"B\u00e1ez-Santos, Y. M., John, S. E. S. & Mesecar, A. D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21\u201338 (2015).","journal-title":"Antiviral Res."},{"key":"56902_CR51","doi-asserted-by":"publisher","first-page":"eade1985","DOI":"10.1126\/scisignal.ade1985","volume":"16","author":"Y Xiong","year":"2023","unstructured":"Xiong, Y. et al. The substrate selectivity of papain-like proteases from human-infecting coronaviruses correlates with innate immune suppression. Sci. Signal. 16, eade1985 (2023).","journal-title":"Sci. Signal."},{"key":"56902_CR52","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.molcel.2017.10.003","volume":"68","author":"CD Swaim","year":"2017","unstructured":"Swaim, C. D., Scott, A. F., Canadeo, L. A. & Huibregtse, J. M. Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin receptor. Mol. Cell 68, 581\u2013590.e585 (2017).","journal-title":"Mol. Cell"},{"key":"56902_CR53","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41579-018-0020-5","volume":"16","author":"YC Perng","year":"2018","unstructured":"Perng, Y. C. & Lenschow, D. J. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 16, 423\u2013439 (2018).","journal-title":"Nat. Rev. Microbiol."},{"key":"56902_CR54","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.tim.2023.07.006","volume":"31","author":"L Sarkar","year":"2023","unstructured":"Sarkar, L., Liu, G. & Gack, M. U. ISG15: its roles in SARS-CoV-2 and other viral infections. Trends Microbiol. 31, 1262\u20131275 (2023).","journal-title":"Trends Microbiol."},{"key":"56902_CR55","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1038\/s41590-021-01035-8","volume":"22","author":"D Munnur","year":"2021","unstructured":"Munnur, D. et al. Altered ISGylation drives aberrant macrophage-dependent immune responses during SARS-CoV-2 infection. Nat. Immunol. 22, 1416\u20131427 (2021).","journal-title":"Nat. Immunol."},{"key":"56902_CR56","doi-asserted-by":"publisher","first-page":"104661","DOI":"10.1016\/j.antiviral.2019.104661","volume":"174","author":"JR Clasman","year":"2020","unstructured":"Clasman, J. R., Everett, R. K., Srinivasan, K. & Mesecar, A. D. Decoupling deISGylating and deubiquitinating activities of the MERS virus papain-like protease. Antiviral Res. 174, 104661 (2020).","journal-title":"Antiviral Res."},{"key":"56902_CR57","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01734-19","volume":"94","author":"X Deng","year":"2020","unstructured":"Deng, X. et al. Structure-guided mutagenesis alters deubiquitinating activity and attenuates pathogenesis of a murine coronavirus. J. Virol. 94, e01734-19 (2020).","journal-title":"J. Virol."},{"key":"56902_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36754-z","volume":"14","author":"SK Myeni","year":"2023","unstructured":"Myeni, S. K. et al. Engineering potent live attenuated coronavirus vaccines by targeted inactivation of the immune evasive viral deubiquitinase. Nat. Commun. 14, 1141 (2023).","journal-title":"Nat. Commun."},{"key":"56902_CR59","doi-asserted-by":"publisher","first-page":"e1012100","DOI":"10.1371\/journal.ppat.1012100","volume":"20","author":"M van Huizen","year":"2024","unstructured":"van Huizen, M. et al. Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo. PLoS Pathog. 20, e1012100 (2024).","journal-title":"PLoS Pathog."},{"key":"56902_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.106634","volume":"26","author":"DY Chen","year":"2023","unstructured":"Chen, D. Y. et al. Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. iScience 26, 106634 (2023).","journal-title":"iScience"},{"key":"56902_CR61","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3390\/v13091743","volume":"13","author":"X Deng","year":"2021","unstructured":"Deng, X. et al. Breakthrough infections with multiple lineages of SARS-CoV-2 variants reveals continued risk of severe disease in immunosuppressed patients. Viruses 13, 1743 (2021).","journal-title":"Viruses"},{"key":"56902_CR62","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1107\/S0907444913000061","volume":"69","author":"PR Evans","year":"2013","unstructured":"Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta. Crystallogr. D Biol. Crystallogr. 69, 1204\u20131214 (2013).","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"key":"56902_CR63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1107\/S0907444911007773","volume":"67","author":"C Vonrhein","year":"2011","unstructured":"Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta. Crystallogr. D Biol. Crystallogr. 67, 293\u2013302 (2011).","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"key":"56902_CR64","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"56902_CR65","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta. Crystallogr. D Biol. Crystallogr. 60, 2126\u20132132 (2004).","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"key":"56902_CR66","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1107\/S0907444912001308","volume":"68","author":"PV Afonine","year":"2012","unstructured":"Afonine, P. V. et al. Towards automated crystallographic structure refinement with phenix.refine. Acta. Crystallogr. D Biol. Crystallogr. 68, 352\u2013367 (2012).","journal-title":"Acta. Crystallogr. D Biol. Crystallogr."},{"key":"56902_CR67","unstructured":"Smart, O. S. et al. Grade2 version 1.6.0. Cambridge, United Kingdom: Global Phasing Ltd. (2021)."},{"key":"56902_CR68","doi-asserted-by":"publisher","first-page":"20697","DOI":"10.1021\/jacs.1c08060","volume":"143","author":"C Ma","year":"2021","unstructured":"Ma, C. et al. Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 main protease inhibitors with high target specificity. J. Am. Chem. Soc. 143, 20697\u201320709 (2021).","journal-title":"J. Am. Chem. Soc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56902-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56902-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56902-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T06:11:05Z","timestamp":1739427065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56902-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56902"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56902-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rutgers, the State University of New Jersey, has applied for a patent US2024382494A1 covering the PL\n                      pro\n                      inhibitors reported in this study and related compounds, which has been published and is pending. J.W. is listed as an inventor. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1604"}}